NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

尿素循環異常症治療市場:療法類型(氨基酸補充品,苯丁酸鈉等),酵素缺損的類型,給藥途徑,流通管道,地區規模,佔有率,預測,機會分析(2020年∼2027年)

Urea Cycle Disorders Treatment Market, by Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, & Others, Enzyme Deficiency Type, Route of Administration, Distribution Channel, Region-Size, Share, Outlook, Opportunity Analysis, 2020-2027

出版商 Coherent Market Insights 商品編碼 1009424
出版日期 內容資訊 英文 272 Pages
商品交期: 2-3個工作天內
價格
尿素循環異常症治療市場:療法類型(氨基酸補充品,苯丁酸鈉等),酵素缺損的類型,給藥途徑,流通管道,地區規模,佔有率,預測,機會分析(2020年∼2027年) Urea Cycle Disorders Treatment Market, by Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, & Others, Enzyme Deficiency Type, Route of Administration, Distribution Channel, Region-Size, Share, Outlook, Opportunity Analysis, 2020-2027
出版日期: 2021年05月24日內容資訊: 英文 272 Pages
簡介

全球尿素循環障礙治療市場包括各種療法,如氨基酸補充劑、苯丁酸鈉、苯丁酸甘油酯、苯甲酸鈉、低蛋白飲食、卡魯米酸等,用於治療尿素循環障礙等遺傳性疾病,影響各種參與人體系統尿素循環途徑的酶。全球尿素循環異常症治療市場的企業,為了擴大市場上的提供產品,著重採用合併和收購等各種商務策略。再加上主要企業,為了強化市場優勢,著重販賣代理店契約等無機性的策略。

本報告提供全球尿素循環異常症治療市場的相關調查,市場趨勢和機會,成長及阻礙因素,COVID-19的影響,治療類型、酵素缺損的類型、給藥途徑、流通管道、各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場展望

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場概述:治療各類型
    • 市場概述:酵素缺損的各類型
    • 市場概述:各給藥途徑
    • 市場概述:各流通管道
    • 市場概述:各地區
  • Coherent Opportunity Map (COM)

第3章 市場動態,法規,及趨勢分析

  • 成長要素
  • 阻礙因素
  • 市場機會
  • 影響分析
  • 主要的發展
  • 治療方法
  • 為了UCD治療的開發中的新治療方法
  • 合併,合作,收購,協定
  • 開發平台分析
  • 法規方案
  • PEST分析
  • 產品的認證
  • 市場趨勢
  • 流行病學
  • 治療概要
  • 品牌分析
  • 償付方案
  • 處方概要

第4章 全球尿素循環異常症治療市場,COVID-19大流行的影響

  • COVID-19對醫療保健部門全體的影響
  • COVID-19流行病學
  • COVID-19供應鏈的影響
  • Covid-19臨床試驗和醫藥品開發的影響

第5章 全球尿素循環異常症治療市場:各療法類型(2016-2027)

  • 簡介
  • 氨基酸補充品
  • 苯丁酸鈉
  • 甘油苯基丁酸酯
  • 苯甲酸鈉
  • 其他(低蛋白質食,木糖酸等)

第6章 全球尿素循環異常症治療市場:酵素缺損的各類型(2016-2027)

  • 簡介
  • 市場佔有率分析(2020,2027)
  • 與前一年同期比較成長分析(2017-2027)
  • 市場區隔趨勢
  • OTC - Ornithine Transcarbamylase
  • AS - Argininosuccinate Synthetase
  • AG - Arginase
  • AL - Argininosuccinate Lyase
  • CPS1 - Carbamoyl Phosphate Synthase
  • NAGS - N-acetylglutamate Synthase

第7章 全球尿素循環異常症治療市場:各給藥途徑(2016-2027)

  • 簡介
  • 口服
  • 注射

第8章 全球尿素循環異常症治療市場:各流通管道(2016-2027)

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第9章 全球尿素循環異常症治療市場:各地區(2016-2027)

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • GCC
  • 以色列
  • 其他中東
  • 非洲
  • 南非
  • 中非
  • 北非

第10章 競爭情形

  • 企業簡介
    • Bausch Health Companies, Inc.
    • Recordati Rare Diseases Inc.
    • Lucane Pharma SA
    • Acer Therapeutics
    • Ultragenyx Pharmaceutical Inc.
    • Aeglea BioTherapeutics
    • Arcturus Therapeutics Holdings Inc.
    • Orpharma Pty Ltd.
    • Selecta Biosciences, Inc.
    • Abbott Laboratories
    • NESTLE SA
    • DANONE SA
    • Mead Johnson &Company, LLC
目錄

The global urea cycle disorders treatment market includes various therapies such as amino acid supplements, sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, low protein diet, carglumic acid, etc. for the treatment of the inherited disorder such as urea cycle disorders, which affects various enzymes taking part in the urea cycle pathway in the human system. The urea cycle disorders are classified according to the deficiencies observed in different enzymes of the urea cycle such as OTC - ornithine transcarbamylase, ASD - argininosuccinic acid synthetase (citrullinemia), AG - Arginase, ALD - argininosuccinase acid lyase (argininosuccinic aciduria), CPS - carbamoyl phosphate synthetase, and NAGS - N-acetylglutamate synthetase.

Market Dynamics

Market players are focused on adopting different business strategies such as mergers and acquisitions in order to expand their offerings in the market.

For instance, in February 2017, Mead Johnson Nutrition Company (MJN) announced its merger with Reckitt Benckiser Group plc (RB). Mead Johnson, now a division of RB, added its globally-recognized brands, including Enfa and Nutramigen, which are used in dietary management of urea cycle disorder, to RB's consumer health portfolio, thus strengthening its position globally.

Moreover, For Instance, In October 2017, Lucane Pharma SA was acquired by the Eurocept Pharmaceuticals, a company developing, distributing, and marketing of medicinal products in therapeutic areas such as anesthesia, oncology, immunology, and neurology. This acquisition has aided Eurocept Pharmaceuticals to invest in research and development of medicines for rare metabolic diseases such as urea cycle disorders.

Furthermore, Key players focused on inorganic strategies such as distribution agreements in order to strengthen their presence in the market.

For Instance, In 2016, Horizon Pharma plc and Swedish Orphan Biovitrum AB (publ) (Sobi), a biotechnological company in Sweden, announced the distribution agreement for the distribution of Ravicti in European countries including the U.K,. Germany, Italy, France, and Spain.

Key features of the study:

    • This report provides in-depth analysis of the global urea cycle disorders treatment market, provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020-2027)
    • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
    • It profiles leading players in the global urea cycle disorders treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
    • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future market expansion and marketing tactics
    • The global urea cycle disorders treatment market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
    • Stakeholders would greatly benefit in decision-making through various strategy matrices used in analyzing the global urea cycle disorders treatment market

Detailed Segmentation:

  • Global Urea Cycle Disorders Treatment Market, By Treatment Type:
  • Amino Acid Supplements
  • Sodium Phenylbutyrate
  • Glycerol Phenylbutyrate
  • Sodium Benzoate
  • Others (Low Protein Diet, Carglumic acid, etc.)
  • Global Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type :
  • OTC - Ornithine Transcarbamylase
  • AS - Argininosuccinate Synthetase (citrullinemia)
  • AG - Arginase
  • AL - Argininosuccinate Lyase
  • CPS1 - Carbamoyl Phosphate Synthase
  • NAGS - N-acetylglutamate Synthase
  • Global Urea Cycle Disorders Treatment Market, By Route of Administration :
  • Oral
  • Injectable
  • Global Urea Cycle Disorders Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Urea Cycle Disorders Treatment Market, By Region:
  • North America
    • By Treatment Type:
    • Amino Acid Supplements
    • Sodium Phenylbutyrate
    • Glycerol Phenylbutyrate
    • Sodium Benzoate
    • Others (Low Protein Diet, Carglumic acid, etc.)
    • By Enzyme Deficiency Type:
    • OTC - Ornithine Transcarbamylase
    • AS - Argininosuccinate Synthetase (citrullinemia)
    • AG - Arginase
    • AL - Argininosuccinate Lyase
    • CPS1 - Carbamoyl Phosphate Synthase
    • NAGS - N-acetylglutamate Synthase
    • By Route of Administration :
    • Oral
    • Injecatble
    • By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • U.S.
    • Canada
  • Latin America
    • By Treatment Type:
    • Amino Acid Supplements
    • Sodium Phenylbutyrate
    • Glycerol Phenylbutyrate
    • Sodium Benzoate
    • Others (Low Protein Diet, Carglumic acid, etc.)
    • By Enzyme Deficiency Type:
    • OTC - Ornithine Transcarbamylase
    • AS - Argininosuccinate Synthetase (citrullinemia)
    • AG - Arginase
    • AL - Argininosuccinate Lyase
    • CPS1 - Carbamoyl Phosphate Synthase
    • NAGS - N-acetylglutamate Synthase
    • By Route of Administration :
    • Oral
    • Injecatble
    • By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Treatment Type:
    • Amino Acid Supplements
    • Sodium Phenylbutyrate
    • Glycerol Phenylbutyrate
    • Sodium Benzoate
    • Others (Low Protein Diet, Carglumic acid, etc.)
    • By Enzyme Deficiency Type:
    • OTC - Ornithine Transcarbamylase
    • AS - Argininosuccinate Synthetase (citrullinemia)
    • AG - Arginase
    • AL - Argininosuccinate Lyase
    • CPS1 - Carbamoyl Phosphate Synthase
    • NAGS - N-acetylglutamate Synthase
    • By Route of Administration :
    • Oral
    • Injecatble
    • By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Treatment Type:
    • Amino Acid Supplements
    • Sodium Phenylbutyrate
    • Glycerol Phenylbutyrate
    • Sodium Benzoate
    • Others (Low Protein Diet, Carglumic acid, etc.)
    • By Enzyme Deficiency Type:
    • OTC - Ornithine Transcarbamylase
    • AS - Argininosuccinate Synthetase (citrullinemia)
    • AG - Arginase
    • AL - Argininosuccinate Lyase
    • CPS1 - Carbamoyl Phosphate Synthase
    • NAGS - N-acetylglutamate Synthase
    • By Route of Administration :
    • Oral
    • Injecatble
    • By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Treatment Type:
    • Amino Acid Supplements
    • Sodium Phenylbutyrate
    • Glycerol Phenylbutyrate
    • Sodium Benzoate
    • Others (Low Protein Diet, Carglumic acid, etc.)
    • By Enzyme Deficiency Type:
    • OTC - Ornithine Transcarbamylase
    • AS - Argininosuccinate Synthetase (citrullinemia)
    • AG - Arginase
    • AL - Argininosuccinate Lyase
    • CPS1 - Carbamoyl Phosphate Synthase
    • NAGS - N-acetylglutamate Synthase
    • By Route of Administration :
    • Oral
    • Injecatble
    • By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country/Region:
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Treatment Type:
    • Amino Acid Supplements
    • Sodium Phenylbutyrate
    • Glycerol Phenylbutyrate
    • Sodium Benzoate
    • Others (Low Protein Diet, Carglumic acid, etc.)
    • By Enzyme Deficiency Type:
    • OTC - Ornithine Transcarbamylase
    • AS - Argininosuccinate Synthetase (citrullinemia)
    • AG - Arginase
    • AL - Argininosuccinate Lyase
    • CPS1 - Carbamoyl Phosphate Synthase
    • NAGS - N-acetylglutamate Synthase
    • By Route of Administration :
    • Oral
    • Injecatble
    • By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
  • Bausch Health Companies, Inc.*
    • Company Overview
    • Material Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Recordati Rare Diseases Inc.
  • Lucane Pharma SA
  • Acer Therapeutics
  • Ultragenyx Pharmaceutical Inc.
  • Aeglea BioTherapeutics
  • Arcturus Therapeutics Holdings Inc.
  • Orpharma Pty Ltd.
  • Selecta Biosciences, Inc.
  • Abbott Laboratories
  • NESTLE S.A.
  • DANONE S.A.
  • Mead Johnson & Company, LLC

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Treatment Type
    • Market Snapshot, By Enzyme Deficiency Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Drivers
  • Restraints
  • Opportunities
  • Impact Analysis
  • Key Developments
  • Treatment Approaches
  • Novel Therapies Under Development for the Treatment of UCD
  • Mergers, Collaborations, Acquisitions & Agreements
  • Pipeline Analysis
  • Regulatory Scenario
  • PEST Analysis
  • Product Approvals
  • Market Trends
  • Epidemiology
  • Therapeutics Overview
  • Brand Analysis
  • Reimbursement Scenario
  • Prescription Overview

4. Global Urea Cycle Disorders Treatment Market, Impact of COVID-19 Pandemic

  • COVID-19 Impact on Overall Healthcare Sector
  • COVID-19 Epidemiology
  • Impact of COVID-19 Impact on Supply Chain
  • Covid-19 Impact on Clinical Trials and Drug Development

5. Global Urea Cycle Disorders Treatment Market, By Treatment Type, 2016-2027 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017-2027
    • Segment Trends
    • Amino Acid Supplements
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Sodium Phenylbutyrate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Glycerol Phenylbutyrate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Sodium Benzoate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Others (Low Protein Diet, Carglumic acid, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

6. Global Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • OTC - Ornithine Transcarbamylase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • AS - Argininosuccinate Synthetase (citrullinemia)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • AG - Arginase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • AL - Argininosuccinate Lyase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • CPS1 - Carbamoyl Phosphate Synthase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • NAGS - N-acetylglutamate Synthase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

7. Global Urea Cycle Disorders Treatment Market, By Route of Administration, 2016-2027 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017-2027
    • Segment Trends
    • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

8. Global Urea Cycle Disorders Treatment Market, By Distribution Channel, 2016-2027 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017-2027
    • Segment Trends
    • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

9. Global Urea Cycle Disorders Treatment Market, By Region, 2016-2027 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Country, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Countries, 2017-2027
  • North America
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Enzyme Deficiency Type, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Enzyme Deficiency Type, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Enzyme Deficiency Type, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Enzyme Deficiency Type, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Enzyme Deficiency Type, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Treatment Type, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Enzyme Deficiency Type, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016-2027 (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa

10. Competitive Landscape

  • Company Profiles
    • Bausch Health Companies, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Recordati Rare Diseases Inc.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Lucane Pharma SA
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Acer Therapeutics
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Ultragenyx Pharmaceutical Inc.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Aeglea BioTherapeutics
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Arcturus Therapeutics Holdings Inc.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Orpharma Pty Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Selecta Biosciences, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Abbott Laboratories
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • NESTLE S.A.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • DANONE S.A.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Mead Johnson & Company, LLC
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies